Emrosi's accelerating prescription growth (11% QoQ) and expanded payer access to 85% of commercial lives signal a durable growth trajectory. Watch for Q2 2026 Emrosi revenue to potentially exceed $7-8M as the GPO contract ramps, which would further validate the product's market penetration.
Price Chart
Executive Summary
Journey Medical reported Q1 2026 revenue of $16.0M (+21% YoY) and a GAAP net loss of $(0.08) per share, narrowing from $(0.18) a year ago. Emrosi revenue grew 3x to $6.3M, and cash increased to $27.2M, but gross margin contracted to 61.0% due to a $1.3M non-recurring inventory write-down.
Key Financial Metrics
Key Facts
- Total revenue $16.0M for Q1 2026, up 21% from $13.1M in Q1 2025
- Emrosi revenue $6.3M vs $2.1M in prior-year quarter, a 200% increase
- GAAP net loss narrowed to $(2.2M) or $(0.08)/share from $(4.1M) or $(0.18)/share
- Adjusted EBITDA turned positive at $0.6M vs $(0.9M) a year ago
- Cash and equivalents $27.2M at March 31, 2026, up from $24.1M at Dec 31, 2025
- Gross margin declined to 61.0% from 63.5% due to $1.3M non-recurring API inventory write-down
- Emrosi prescriptions totaled 29,968 in Q1 2026 vs 27,023 in Q4 2025
- Secured GPO contract covering ~85% of U.S. commercial lives for Emrosi
Financial Impact
Revenue growth of $2.9M YoY; net loss improvement of $1.9M; cash increase of $3.1M
Risk Factors
- Gross margin compression from non-recurring inventory charges may recur if additional API write-downs are needed
- Accutane revenue continues to decline due to competitive pressures, partially offsetting Emrosi growth
- Company remains unprofitable on a GAAP basis with accumulated deficit of $100.7M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-060232 |
| Document: tm2614268d1_8k.htm | 0001104659-26-060232 |
| Document: 0001104659-26-060232-index-headers.html | 0001104659-26-060232 |
| Document: 0001104659-26-060232-index.html | 0001104659-26-060232 |
| Document: 0001104659-26-060232.txt | 0001104659-26-060232 |
| 8-K Data (Synthetic) | 0001104659-26-060232 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G/A | $6.31 | awaiting T+20 | — | $5.09 (−19.33%) |
Aug 15, 2026 10w ago | Institutional Cluster | $6.46 $7.36 | ▲ +13.93% | ▲ +15.91% | $5.09 (−21.21%) |
Aug 12, 2026 10w ago | 8-K | $6.65 $7.23 | ▲ +8.72% | ▲ +10.47% | $5.09 (−23.46%) |
Aug 12, 2026 10w ago | Press Release | $6.65 $7.23 | ▼ −8.72% | ▼ −10.47% | $5.09 (+23.46%) |
May 13, 2026 23w ago | 8-K | $6.35 $6.34 | ▼ −0.16% | ▲ +0.70% | $5.09 (−19.84%) |
May 6, 2026 24w ago | Press Release | $5.00 $6.06 | ▲ +21.20% | ▲ +18.06% | $5.09 (+1.80%) |
Apr 21, 2026 27w ago | Press Release | $4.92 $6.25 | ▲ +27.03% | ▲ +22.12% | $5.09 (+3.46%) |
Mar 25, 2026 30w ago | Press Release | $4.78 $5.15 | ▲ +7.74% | ▼ −2.92% | $5.09 (+6.49%) |
Mar 18, 2026 31w ago | Press Release | $7.12 $5.17 | ▼ −27.39% | ▼ −33.43% | $5.09 (−28.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers